skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: PubMed Central remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Abstract 1601 Use of Interactive Progress Curves in an OER to Teach Kinetics in Biochemistry
Abstract 1601 Use of Interactive Progress Curves in an OER to Teach Kinetics in Biochemistry
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract 1601 Use of Interactive Progress Curves in an OER to Teach Kinetics in Biochemistry

Jakubowski, Henry ; Agnew, Henry ; Jardine, Bartholomew ; Sauro, Herbert

The Journal of biological chemistry, 2024-03, Vol.300 (3) [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
2
Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies
Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies

Jonasch, Eric ; Call, Justin ; Kambhampati, Swetha ; Caimi, Paolo ; Curti, Brendan ; Diefenbach, Catherine ; Heath, Elisabeth ; Park, Steven ; Kornblum, Noah ; Li, Weidong ; Reimers, Melissa ; Spurgeon, Stephen ; Vaishampayan, Ulka ; Ye, Dingwei ; Zhang, Li ; Zhao, Weili ; Chen, Zhu ; Hunder, Naomi ; Ma, Sharon ; Song, Eric ; Garmezy, Benjamin

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S14-S15 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
3
LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma
LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma

McDermott, David F ; Peer, Avivit ; Agarwal, Neeraj ; Atkins, Michael B ; Cornell, Jerry ; Perini, Rodolfo F ; Grossmann, Kenneth F ; Gurney, Howard

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S11-S11 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
4
Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma
Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma

Beckermann, Kathryn ; Rini, Brian ; Haas, Naomi ; George, Daniel ; Jonasch, Eric

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S13-S14 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
5
Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002
Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002
Material Type:
Artigo 		Adicionar ao Meu Espaço

Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002

Motzer, Robert J ; Choueiri, Toni K ; Garmezy, Benjamin ; O’Neil, Bert ; Michalski, Joel ; Barata, Pedro ; Bajaj, Aung ; Chahoud, Jad ; Liu, Mohan ; Xu, Fiona ; Andrianova, Svetlana ; Shah, Neil ; McGregor, Bradley

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S10-S11 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
6
NRG-GU012: randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI)
NRG-GU012: randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI)
Material Type:
Artigo 		Adicionar ao Meu Espaço

NRG-GU012: randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI)

McKay, Rana

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S12-S13 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
7
STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC
STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC
Material Type:
Artigo 		Adicionar ao Meu Espaço

STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC

Hasanov, Elshad ; Flynt, Lesley ; Slack Tidwell, Rebecca ; Hwang, Hyunsoo ; Brooks, Roserika ; King, Lauren ; Solley, Travis ; Syed, Mashaal ; Yamamura, Yuko ; Hayward, Colin ; Venkatesan, Aradhana M ; Jonasch, Eric

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S13-S13 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
8
SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma
SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma

Chouieri, Toni

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S11-S12 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
9
A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC
A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC

Jonasch, Eric ; Hauke, Ralph ; Falchook, Gerald ; Logan, Theodore ; Gordon, Michael ; Hall, Evan ; Schuch, Brian ; Bilen, Mehmet A ; Naqash, Abdul ; Zakaharia, Yousef ; Ryan, Christopher W ; Lally, Satwant ; Xiao, Jim ; Zimmerman, Zachary ; Srinivasan, Ramaprasad ; Choueiri, Toni K

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S12-S12 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
10
OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)
OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)

Beckermann, Kathryn ; Haake, Scott ; Reddy, Anupama ; Shyr, Yu ; Kimryn Rathmell, W ; Pal, Sumanta ; Ornstein, Moshe ; Barata, Pedro ; Zhang, Tian ; Rini, Brian

The oncologist (Dayton, Ohio), 2023-08, Vol.28 (Supplement_1), p.S14-S14 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (7.162)
  2. Revistas revisadas por pares (2.040)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (7.411)
  2. Resenhas  (14)
  3. Web Resources  (1)
  4. Reports  (1)
  5. magazinearticle  (1)
  6. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1968  (5.219)
  2. 1968Até1981  (136)
  3. 1982Até1995  (468)
  4. 1996Até2010  (277)
  5. Após 2010  (1.329)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (7.326)
  2. Japonês  (114)
  3. Chinês  (59)
  4. Francês  (45)
  5. Português  (11)
  6. Alemão  (9)
  7. Espanhol  (7)
  8. Italiano  (2)
  9. Coreano  (2)
  10. Africâner  (1)
  11. Holandês  (1)
  12. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.